Sanofi News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Orderbuch			Analysen
Historisch

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Orderbuch

Analysen

Historisch

27.03.18	Sanofi: FDA Approves Toujeo Max SoloStar Pen - Quick Facts (RTTNews)
15.03.18	Sanofi Prices EUR 8 Bln Of Bond Issues - Quick Facts (RTTNews)
15.03.18	Sanofi successfully prices EUR 8 billion of bond issues (GlobeNewswire)
12.03.18	SVRA Disappoints, SNY/REGN's Praluent Price To Be Cut, OBSV On Watch (RTTNews)
10.03.18	Regeneron, Sanofi To Cut Heart Drug's Price; Say Praluent Lowers Risk Of Death (RTTNews)
10.03.18	Sanofi and Regeneron announce plans to make Praluent® more accessible and affordable for patients with the greatest health risk and unmet need (GlobeNewswire)
10.03.18	Sanofi: Praluent® (alirocumab) significantly reduced risk of cardiovascular events in high-risk patients, and was associated with lower death rate (GlobeNewswire)
08.03.18	Sanofi Completes Acquisition of Bioverativ Inc. (GlobeNewswire)
08.03.18	Evotec, Sanofi In Talks For Infectious Disease Open Innovation R&D Platform (RTTNews)
08.03.18	Evotec and Sanofi in exclusive talks to create an Evotec-led Infectious Disease open innovation R&D platform (GlobeNewswire)
07.03.18	Sanofi: Filing of the 2017 U.S. Form 20-F and French « Document de Référence » containing the Annual Financial Report (GlobeNewswire)
06.03.18	Sanofi's Board of Directors Proposes Appointment of Emmanuel Babeau as New Independent Director (GlobeNewswire)
04.03.18	An Ear To The Pharma: 7 Stocks To Watch This Week (RTTNews)
02.03.18	Sanofi:FDA Reviews DUPIXENT As Potential Treatment For Moderate-to-Severe Asthma (RTTNews)
02.03.18	Sanofi : FDA to review Dupixent® (dupilumab) as potential treatment for moderate-to-severe asthma (GlobeNewswire)
01.03.18	Sanofi Receives Antitrust Clearances For Proposed Acquisition Of Ablynx (RTTNews)
01.03.18	Sanofi Announces Receipt of Antitrust Clearances in Connection with the Acquisition of Ablynx (GlobeNewswire)
23.02.18	Sanofi Gets U.S. Regulatory Approval For Proposed Acquisition Of Bioverativ (RTTNews)
23.02.18	Sanofi: Hart-Scott-Rodino waiting period expires for Sanofi's acquisition of Bioverativ (GlobeNewswire)
19.02.18	Aeras Reports Results From Phase 2 Tuberculosis Vaccine Trial - Quick Facts (RTTNews)
08.02.18	Sanofi Launches Tender Offer To Acquire Bioverativ At $105/share In Cash (RTTNews)
08.02.18	Sanofi Commences Tender Offer for Acquisition of Bioverativ Inc. (GlobeNewswire)
07.02.18	Sanofi Q4 Profit Down; Ups Dividend; Sees Growth In FY18 Business Earnings (RTTNews)
07.02.18	Sanofi Q4 Profit Plunges, Lifts Dividend; Sees Growth In FY18 Business EPS (RTTNews)
31.01.18	Sanofi: Sanofi, DNDi seek European Medicines Agency review for sleeping sickness treatment (GlobeNewswire)
29.01.18	Ablynx Stock Climbs On Deal To Be Bought By Sanofi In EUR 3.9 Bln Deal (RTTNews)
29.01.18	Sanofi To Buy Belgium's Ablynx For EUR 3.9 Bln - Quick Facts (RTTNews)
29.01.18	Sanofi to acquire Ablynx for €3.9 Billion (GlobeNewswire)
24.01.18	Sanofi Estimates Negative Currency Impact On Q4 Sales To Be Around 6% - 6.5% (RTTNews)
23.01.18	Sanofi: Availability of the Pre-quarterly Results Communication (GlobeNewswire)
23.01.18	ARRY Shines A BEACON, So Long To JUNO And BIVV, Exciting Time Ahead For GEMP (RTTNews)
22.01.18	Regeneron Announces Approval Of DUPIXENT In Japan - Quick Facts (RTTNews)
22.01.18	Sanofi In Deal To Buy Hemophilia Drugmaker Bioverativ For $11.6 Bln; Stock Dips (RTTNews)
22.01.18	Sanofi To Purchase Bioverativ For $105 Per Share In Cash - Quick Facts (RTTNews)
22.01.18	Sanofi to Acquire Bioverativ for $11.6 Billion (GlobeNewswire)
22.01.18	WSJ : Sanofi Nears Deal To Buy Bioverativ For More Than $11.5 Bln (RTTNews)
19.01.18	Sanofi Appoints Dominique Carouge Executive Vice President Head of Business Transformation and Member of the Executive Committee (GlobeNewswire)
08.01.18	Sanofi, Regeneron To Expand Investment For Cemiplimab & Dupilumab Development (RTTNews)
08.01.18	Sanofi and Regeneron to accelerate and expand investment for cemiplimab and dupilumab development programs (GlobeNewswire)
08.01.18	Sanofi And Alnylam Restructure RNAi Therapeutics Rare Disease Alliance (RTTNews)
07.01.18	Sanofi and Alnylam enter into strategic restructuring of RNAi therapeutics rare disease alliance (GlobeNewswire)
07.01.18	New Drugs Approved In December (RTTNews)
27.12.17	Biotech Stocks Facing FDA Decision In January 2018 (RTTNews)
18.12.17	Sanofi, Alnylam Submit MAA To European Medicines Agency For Patisiran (RTTNews)
18.12.17	Sanofi and Alnylam submit Marketing Authorization Application to the European Medicines Agency for patisiran for the treatment of hereditary ATTR amyloidosis (GlobeNewswire)
15.12.17	Alnylam Pharma Announces FDA's Decision To Lift Clinical Hold On Fitusiran (RTTNews)
15.12.17	Sanofi: FDA lifts clinical hold on fitusiran (GlobeNewswire)
13.12.17	Sanofi : Sanofi presents R&D strategy and innovative pipeline (GlobeNewswire)
13.12.17	Regeneron, Sanofi Report Results For PD-1 Antibody Cemiplimab In Advanced CSCC (RTTNews)
13.12.17	Sanofi and Regeneron announce positive topline pivotal results for PD-1 antibody cemiplimab in advanced cutaneous squamous cell carcinoma (GlobeNewswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Part Grp Hldg	1’263.50	2.89 %	K V
Sonova Hldg	312.10	2.66 %	K V
Novartis	93.68	2.32 %	K V
Geberit	526.80	1.97 %	K V
Roche Hldg G	254.30	1.27 %	K V
Kuehne+Nagel Int	209.50	0.72 %	K V
UBS Group	28.30	0.57 %	K V
Givaudan	3’933.00	0.36 %	K V
Nestle	76.00	0.05 %	K V
Lonza Grp	521.40	-0.04 %	K V

mehr

22.11.24		Dow Jones aktuell: Dow Jones zum Ende des Freitagshandels in der Gewinnzone
22.11.24		S&P 500-Handel aktuell: S&P 500 liegt letztendlich im Plus
22.11.24		Freundlicher Handel: NASDAQ 100 verbucht zum Ende des Freitagshandels Zuschläge
22.11.24		Gute Stimmung in New York: nachmittags Pluszeichen im S&P 500
22.11.24		Gewinne in New York: NASDAQ 100 präsentiert sich fester
22.11.24		Freundlicher Handel in New York: Dow Jones präsentiert sich am Freitagnachmittag fester
22.11.24		Börse New York in Grün: Dow Jones bewegt sich am Mittag im Plus

22.11.24

Dow Jones aktuell: Dow Jones zum Ende des Freitagshandels in der Gewinnzone

22.11.24

S&P 500-Handel aktuell: S&P 500 liegt letztendlich im Plus

22.11.24

Freundlicher Handel: NASDAQ 100 verbucht zum Ende des Freitagshandels Zuschläge

22.11.24

Gute Stimmung in New York: nachmittags Pluszeichen im S&P 500

22.11.24

Gewinne in New York: NASDAQ 100 präsentiert sich fester

22.11.24

Freundlicher Handel in New York: Dow Jones präsentiert sich am Freitagnachmittag fester